Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin

Mice bearing the P388/S or P388/ADR (doxorubicin-resistant) leukemia were treated with menogaril or mitoxantrone. Both drugs were highly effective against P388/S but were ineffective against the doxorubicin-resistant subline, indicating cross-resistance. These observations may be of use in the desig...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reports Vol. 71; no. 2; p. 195
Main Authors Chandrasekaran, B, Dimling, J, Capizzi, R L
Format Journal Article
LanguageEnglish
Published United States 01.02.1987
Subjects
Animals
Antineoplastic Agents
Body Weight - drug effects
Cell Line
Daunorubicin - analogs & derivatives
Doxorubicin - pharmacology
Drug Resistance
Leukemia P388 - drug therapy
Life Expectancy
Menogaril
Mice
Mice, Inbred Strains
Mitoxantrone - pharmacology
Nogalamycin - analogs & derivatives
Nogalamycin - pharmacology
Online AccessGet more information

Cover

More Information
Summary:Mice bearing the P388/S or P388/ADR (doxorubicin-resistant) leukemia were treated with menogaril or mitoxantrone. Both drugs were highly effective against P388/S but were ineffective against the doxorubicin-resistant subline, indicating cross-resistance. These observations may be of use in the design of clinical trials with these drugs.
ISSN:0361-5960